Skip to main content
Delfa

← All assets

Intepirdine

10 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

10

Ongoing

0

Recruiting

0

Completed

8

Sites

477

Countries

27

Endpoints

141

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 141 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
6
Phase 2/3
1
Phase 3
2

Trials by status

Completed
8
Terminated
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
52
Other (unclassified)
42
Safety / tolerability / PK
21
Function / daily living
10
Behavior / neuropsychiatric
8
Caregiver / quality of life
4
Other clinical outcomes
4

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 56 of 141 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

28

Mini-Mental State Examination (MMSE)Cognition

12

ADCS-Activities of Daily Living (ADCS-ADL)Function

8

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

6

Neuropsychiatric Inventory (NPI)Behavior

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

10 of 10

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT02585934Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

Intepirdine

Alzheimer’s disease

MMSE 12-24Ph 3Completed197Sep 2017-results
NCT0258690912-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Intepirdine

Alzheimer’s disease

Age 50-86Ph 3Terminated169Mar 2018-results
NCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Donepezil, Intepirdine

Alzheimer’s disease

mild-to-moderate ADPh 2Completed102May 20101results
NCT00708552Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

Donepezil, Intepirdine

Alzheimer’s disease

mild-to-moderate ADPh 2Completed72Mar 20101results
NCT02669433Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Intepirdine

Lewy body dementia

Dementia with Lewy bodiesPh 2Completed65Dec 2017-results
NCT02928445Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Intepirdine

Lewy body dementia

Age 50-86Ph 2/3Terminated56Feb 2018-
NCT00224497A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease

Intepirdine

Alzheimer’s disease

mild-to-moderate ADPh 2Completed48--
NCT00348192SB-742457 And Donepezil In Alzheimer's Disease

Donepezil, Intepirdine

Alzheimer’s disease

mild-to-moderate ADPh 2Completed26-1
NCT02910102Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Intepirdine

Alzheimer’s disease, Lewy body dementia

Multiple dementia etiologiesPh 2Completed11Nov 2017-results
NCT00551772A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.

Intepirdine

Alzheimer’s disease

Age 60-85Ph 1Completed1--

Showing 1-10 of 10 trials